Pub. Date : 2009 Oct 31
PMID : 19878585
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | METHODS: Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 2 | RESULTS: Both BRAF RNAi and sorafenib inhibited proliferation in all the cell lines independently of the genetic background, mostly in cells with BRAF(V600E) mutation. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 3 | In the case of sorafenib treatment, cells harbouring BRAF(V600E) mutation showed increase levels of apoptosis due to a balance of the anti-apoptotic proteins Mcl-1 and Bcl-2. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 4 | We have shown that in thyroid cancer cells sorafenib induces apoptosis by affecting Mcl-1 and Bcl-2 in BRAF(V600E) mutated cells which was independent of BRAF. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 5 | We have shown that in thyroid cancer cells sorafenib induces apoptosis by affecting Mcl-1 and Bcl-2 in BRAF(V600E) mutated cells which was independent of BRAF. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 6 | These results suggest that sorafenib may prove useful in the treatment of thyroid carcinomas, particularly those refractory to conventional treatment and harbouring BRAF mutations. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |